MedTrace Logo

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

NCT05987696 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-02-11

No results posted yet for this study

Summary

This is a phase 1, first-in-human (FIH), open-label, multicohort study to evaluate the safety, tolerability and preliminary efficacy of iPSC NK cells in patients with relapsed/refractory AML or AML Minimal Residual Disease (MRD).

Conditions

  • AML, Adult
  • Minimal Residual Disease

Interventions

DRUG

CD33/CLL1 dual CAR-NK cell

NK cell therapy

DRUG

Cyclophosphamid

Lympho-conditioning Agent

DRUG

Fludarabine

Lympho-conditioning Agent

DRUG

Cytarabine

Lympho-conditioning Agent

DRUG

CD33 CAR-NK cell

NK cell therapy

DRUG

super NK cell

NK cell therapy

Sponsors & Collaborators

  • Hangzhou Qihan Biotech Co., Ltd.

    collaborator INDUSTRY

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-31
Primary Completion
2025-01-17
Completion
2025-01-17

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05987696 on ClinicalTrials.gov